Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05513001




Registration number
NCT05513001
Ethics application status
Date submitted
22/08/2022
Date registered
23/08/2022
Date last updated
19/11/2024

Titles & IDs
Public title
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
Scientific title
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies
Secondary ID [1] 0 0
2022-001034-11
Secondary ID [2] 0 0
CLOU064A2303B
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Spontaneous Urticaria 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions
Inflammatory and Immune System 0 0 0 0
Allergies
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - LOU064 (blinded)
Treatment: Drugs - Placebo
Treatment: Drugs - LOU064 (open label)

Experimental: Arm 1: LOU064 (blinded) - LOU064 (blinded) taken orally for 24 weeks, followed by cycles of either LOU064 (open-label) taken orally for a maximum of 5 cycles of 24 weeks each OR treatment-free observation cycles. Randomized in a 1:1 ratio (arm 1:arm 2)

Placebo comparator: Arm 2: LOU064 Placebo (blinded) - LOU064 placebo (blinded) taken orally for 24 weeks, followed by cycles of either LOU064 (open-label) taken orally for a maximum of 5 cycles of 24 weeks each OR treatment-free observation cycles. Randomized in a 1:1 ratio (arm 1:arm 2)

Experimental: Arm 3: LOU064 (Open Label) - LOU064 (open-label) taken orally for 24 weeks per treatment cycle (Arm 3)


Treatment: Drugs: LOU064 (blinded)
LOU064 (blinded) active treatment

Treatment: Drugs: Placebo
Placebo

Treatment: Drugs: LOU064 (open label)
LOU064 (open-label) active treatment
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to first composite event (i.e., relapse (UAS7=16)
Timepoint [1] 0 0
24 weeks
Secondary outcome [1] 0 0
Number of participants with treatment-emergent (serious and non-serious) adverse events
Timepoint [1] 0 0
160 weeks

Eligibility
Key inclusion criteria
* Written informed consent must be obtained before any assessment is performed.
* Male and female, adult participants =18 years of age.
* Participants who successfully completed the preceding core studies CLOU064A2301, CLOU064A2302, CLOU064A1301, CLOU064A2304 or CLOU064A2305 according to the respective protocols.
* Willing and able to adhere to the study protocol and visit schedule.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Significant bleeding risk or coagulation disorders.
* History of gastrointestinal bleeding.
* Requirement for anti-platelet medication.
* Requirement for anticoagulant medication.
* History or current hepatic disease.
* Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/12/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
13/02/2027
Actual
Sample size
Target
Accrual to date
Final
698
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - East Melbourne
Recruitment hospital [2] 0 0
Novartis Investigative Site - Parkville
Recruitment postcode(s) [1] 0 0
3002 - East Melbourne
Recruitment postcode(s) [2] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Idaho
Country [10] 0 0
United States of America
State/province [10] 0 0
Illinois
Country [11] 0 0
United States of America
State/province [11] 0 0
Indiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Maryland
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
Nebraska
Country [16] 0 0
United States of America
State/province [16] 0 0
New Jersey
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Utah
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
United States of America
State/province [24] 0 0
Wisconsin
Country [25] 0 0
Argentina
State/province [25] 0 0
Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Nueve De Julio
Country [27] 0 0
Argentina
State/province [27] 0 0
Santa Fe
Country [28] 0 0
Argentina
State/province [28] 0 0
Bahia Blanca
Country [29] 0 0
Argentina
State/province [29] 0 0
Capital Federal
Country [30] 0 0
Brazil
State/province [30] 0 0
SP
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Pleven
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Sofia
Country [33] 0 0
Canada
State/province [33] 0 0
Alberta
Country [34] 0 0
Canada
State/province [34] 0 0
New Brunswick
Country [35] 0 0
Canada
State/province [35] 0 0
Ontario
Country [36] 0 0
Canada
State/province [36] 0 0
Quebec
Country [37] 0 0
China
State/province [37] 0 0
Guangdong
Country [38] 0 0
China
State/province [38] 0 0
Guangzhou
Country [39] 0 0
China
State/province [39] 0 0
Hubei
Country [40] 0 0
China
State/province [40] 0 0
Jiangsu
Country [41] 0 0
China
State/province [41] 0 0
Jilin
Country [42] 0 0
China
State/province [42] 0 0
Sichuan
Country [43] 0 0
China
State/province [43] 0 0
Zhejiang
Country [44] 0 0
China
State/province [44] 0 0
Beijing
Country [45] 0 0
China
State/province [45] 0 0
Shanghai
Country [46] 0 0
China
State/province [46] 0 0
Tianjin
Country [47] 0 0
Colombia
State/province [47] 0 0
Antioquia
Country [48] 0 0
Colombia
State/province [48] 0 0
Atlantico
Country [49] 0 0
Colombia
State/province [49] 0 0
Barranquilla
Country [50] 0 0
Colombia
State/province [50] 0 0
Bogota
Country [51] 0 0
Czechia
State/province [51] 0 0
Czech Republic
Country [52] 0 0
Czechia
State/province [52] 0 0
CZE
Country [53] 0 0
Czechia
State/province [53] 0 0
Plzen
Country [54] 0 0
Czechia
State/province [54] 0 0
Praha 5
Country [55] 0 0
Denmark
State/province [55] 0 0
Copenhagen NV
Country [56] 0 0
Denmark
State/province [56] 0 0
Hellerup
Country [57] 0 0
France
State/province [57] 0 0
Angers Cedex 9
Country [58] 0 0
France
State/province [58] 0 0
Antony
Country [59] 0 0
France
State/province [59] 0 0
Bordeaux Cedex
Country [60] 0 0
France
State/province [60] 0 0
Brest
Country [61] 0 0
France
State/province [61] 0 0
Montpellier
Country [62] 0 0
France
State/province [62] 0 0
Nice
Country [63] 0 0
France
State/province [63] 0 0
Paris
Country [64] 0 0
France
State/province [64] 0 0
Pierre Benite
Country [65] 0 0
France
State/province [65] 0 0
Reims
Country [66] 0 0
France
State/province [66] 0 0
Rouen
Country [67] 0 0
France
State/province [67] 0 0
Saint Mande
Country [68] 0 0
France
State/province [68] 0 0
Toulouse
Country [69] 0 0
Germany
State/province [69] 0 0
Bad Bentheim
Country [70] 0 0
Germany
State/province [70] 0 0
Berlin
Country [71] 0 0
Germany
State/province [71] 0 0
Bramsche
Country [72] 0 0
Germany
State/province [72] 0 0
Dresden
Country [73] 0 0
Germany
State/province [73] 0 0
Gottingen
Country [74] 0 0
Germany
State/province [74] 0 0
Halle Saale
Country [75] 0 0
Germany
State/province [75] 0 0
Halle S
Country [76] 0 0
Germany
State/province [76] 0 0
Hannover
Country [77] 0 0
Germany
State/province [77] 0 0
Leipzig
Country [78] 0 0
Germany
State/province [78] 0 0
Luebeck
Country [79] 0 0
Germany
State/province [79] 0 0
Mainz
Country [80] 0 0
Germany
State/province [80] 0 0
Marburg
Country [81] 0 0
Germany
State/province [81] 0 0
Merzig
Country [82] 0 0
Germany
State/province [82] 0 0
Muenchen
Country [83] 0 0
Hungary
State/province [83] 0 0
Hajdu Bihar
Country [84] 0 0
Hungary
State/province [84] 0 0
Debrecen
Country [85] 0 0
India
State/province [85] 0 0
Belgavi
Country [86] 0 0
Italy
State/province [86] 0 0
AN
Country [87] 0 0
Italy
State/province [87] 0 0
MI
Country [88] 0 0
Japan
State/province [88] 0 0
Aichi
Country [89] 0 0
Japan
State/province [89] 0 0
Chiba
Country [90] 0 0
Japan
State/province [90] 0 0
Hokkaido
Country [91] 0 0
Japan
State/province [91] 0 0
Kanagawa
Country [92] 0 0
Japan
State/province [92] 0 0
Kumamoto
Country [93] 0 0
Japan
State/province [93] 0 0
Osaka
Country [94] 0 0
Japan
State/province [94] 0 0
Shimane
Country [95] 0 0
Japan
State/province [95] 0 0
Tokyo
Country [96] 0 0
Japan
State/province [96] 0 0
Hiroshima
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Dalseo Gu
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Gyeonggi Do
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Gwangju
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Incheon
Country [101] 0 0
Korea, Republic of
State/province [101] 0 0
Seoul
Country [102] 0 0
Malaysia
State/province [102] 0 0
Johor
Country [103] 0 0
Malaysia
State/province [103] 0 0
Perak
Country [104] 0 0
Malaysia
State/province [104] 0 0
Wilayah Persekutuan
Country [105] 0 0
Malaysia
State/province [105] 0 0
Pulau Pinang
Country [106] 0 0
Poland
State/province [106] 0 0
Bialystok
Country [107] 0 0
Poland
State/province [107] 0 0
Lodz
Country [108] 0 0
Poland
State/province [108] 0 0
Poznan
Country [109] 0 0
Poland
State/province [109] 0 0
Warszawa
Country [110] 0 0
Puerto Rico
State/province [110] 0 0
Carolina
Country [111] 0 0
Russian Federation
State/province [111] 0 0
Izhevsk
Country [112] 0 0
Russian Federation
State/province [112] 0 0
Ryazan
Country [113] 0 0
Russian Federation
State/province [113] 0 0
St Petersburg
Country [114] 0 0
Russian Federation
State/province [114] 0 0
Stavropol
Country [115] 0 0
Singapore
State/province [115] 0 0
Singapore
Country [116] 0 0
Slovakia
State/province [116] 0 0
Kezmarok
Country [117] 0 0
Slovakia
State/province [117] 0 0
Komarno
Country [118] 0 0
Slovakia
State/province [118] 0 0
Kosice
Country [119] 0 0
Slovakia
State/province [119] 0 0
Levice
Country [120] 0 0
Slovakia
State/province [120] 0 0
Nove Zamky
Country [121] 0 0
Slovakia
State/province [121] 0 0
Svidnik
Country [122] 0 0
South Africa
State/province [122] 0 0
Gauteng
Country [123] 0 0
South Africa
State/province [123] 0 0
Western Province
Country [124] 0 0
Spain
State/province [124] 0 0
Catalunya
Country [125] 0 0
Spain
State/province [125] 0 0
Comunidad Valenciana
Country [126] 0 0
Spain
State/province [126] 0 0
Las Palmas de Gran Canaria
Country [127] 0 0
Spain
State/province [127] 0 0
Madrid
Country [128] 0 0
Spain
State/province [128] 0 0
Valencia
Country [129] 0 0
Switzerland
State/province [129] 0 0
Bern
Country [130] 0 0
Switzerland
State/province [130] 0 0
Zuerich
Country [131] 0 0
Taiwan
State/province [131] 0 0
Taichung
Country [132] 0 0
Taiwan
State/province [132] 0 0
Taipei
Country [133] 0 0
Taiwan
State/province [133] 0 0
Taoyuan
Country [134] 0 0
Thailand
State/province [134] 0 0
Bangkok
Country [135] 0 0
Thailand
State/province [135] 0 0
THA
Country [136] 0 0
Thailand
State/province [136] 0 0
Chiang Mai
Country [137] 0 0
Turkey
State/province [137] 0 0
Aydin
Country [138] 0 0
Turkey
State/province [138] 0 0
Istanbul
Country [139] 0 0
Turkey
State/province [139] 0 0
Izmir
Country [140] 0 0
Turkey
State/province [140] 0 0
Kayseri
Country [141] 0 0
Turkey
State/province [141] 0 0
Sakarya
Country [142] 0 0
Turkey
State/province [142] 0 0
Samsun
Country [143] 0 0
Turkey
State/province [143] 0 0
Talas Kayseri
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Cardiff

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 studies.

This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.
Trial website
https://clinicaltrials.gov/study/NCT05513001
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Country 0 0
Phone 0 0
1-888-669-6682
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05513001